CoQ10 supplementation does not appear to induce persistent downregulations in endogenous production or related pathways after discontinuation, based on available evidence. Most studies (primarily in humans and rodents) show that tissue and plasma levels return to baseline without falling below pretreatment values or causing lasting suppression. However, one rat study suggests a potential transient "withdrawal effect" in myocardial tissue, where levels temporarily dropped below baseline before recovering.

### Analysis of Evidence for Downregulations
I reviewed scientific literature, including pharmacokinetic studies, reviews, and animal/human trials, focusing on effects post-discontinuation. Key findings:

- **No Influence on Endogenous Biosynthesis**: Multiple pharmacokinetic reviews and meta-analyses indicate that exogenous CoQ10 does not suppress or alter the body's natural production of CoQ10 (or its homolog CoQ9 in rodents). Levels elevate during supplementation but do not accumulate excessively in plasma or tissues after cessation. This is supported by human data where biosynthesis remains unaffected.

- **Return to Baseline in Humans**: In a 1-year bioavailability study (90 mg/day for 9 months in 21 healthy adults), plasma CoQ10 levels rose from ~1 mg/L to ~2 mg/L, then returned exactly to pretreatment levels after 3 months of withdrawal, with no drop below baseline or adverse effects noted. Similar patterns are seen in fatigue reduction trials: benefits (e.g., reduced symptoms) wane post-discontinuation, but no rebound worsening or downregulation is reported. In patients with primary CoQ10 deficiency (genetic conditions), discontinuation can lead to symptom deterioration, but this reflects underlying deficiency rather than induced downregulation from supplementation.

- **Transient Effects in Rodents**: Most rodent studies show no downregulation. For example, in mice supplemented lifelong or short-term (up to 17.5 months at 93–371 mg/kg/day), tissue CoQ9/CoQ10 levels increased (contrary to older views of no uptake) without suppressing antioxidant defenses, mitochondrial function, or endogenous content—levels normalized post-sup without issues. However, one rat study (10 mg/kg/day solubilized CoQ10 for 3–6 weeks) reported a "withdrawal effect" in myocardium: CoQ9/CoQ10 levels rose 40–75% during supplementation, but 2 weeks after stopping, they fell 50–60% below control values before recovering to normal by 6 weeks. This hints at possible temporary suppression of endogenous synthesis during high-dose, long-term use, but it's species-specific (rats vs. humans/mice) and not replicated in other tissues or studies.

- **No Persistent Changes in Pathways**:
  - **Biosynthesis (Mevalonate Pathway)**: No evidence of lasting inhibition. Statins (not CoQ10) are the primary cause of reduced endogenous CoQ10.
  - **Mitochondrial ETC/Energy Production**: Function normalizes post-discontinuation without dysfunction.
  - **Antioxidant/Inflammatory**: Markers (e.g., SOD, glutathione, cytokines) revert to baseline; no rebound oxidative stress.
  - **Other**: In statin users, CoQ10 sup alleviates myopathy symptoms, and discontinuation (of statin + CoQ10) improves outcomes without reported withdrawal from CoQ10 itself.

### Estimation of Possibilities
- **Persistent Downregulation**: Very low (<5% likelihood in humans). No human studies show long-term suppression; effects are reversible. In rodents, even the transient drop recovered fully.
- **Transient Downregulation**: Moderate (20–30% in sensitive contexts, e.g., high-dose/long-term in rats). Could occur in myocardium or liver for weeks post-stop, but unconfirmed in humans. Factors like dose (>300 mg/day), duration (>6 months), or concurrent statins/aging may increase risk, but evidence is weak.
- **Overall Safety**: CoQ10 is well-tolerated (up to 1,200 mg/day); rare mild side effects (e.g., nausea) resolve upon discontinuation. No adverse consequences from stopping in non-deficient individuals.

If concerned about discontinuation, taper doses gradually and monitor plasma levels (target 2–4 mg/L during sup). For personalized advice, consult a healthcare provider, especially if on statins or with deficiencies.